title: Primary treatment of condylomata acuminata with viable bacillus Calmette-Guerin.
abstract: OBJECTIVE
  Condylomata acuminata or genital warts are caused by human papillomavirus. Prevalence data show that infection rates are increasing. To our knowledge we report the first successful primary treatment of genital warts with topical bacillus Calmette-Guerin (BCG) and provide long-term followup in a group of adjuvant treated patients with recurrent condylomata acuminata.
  
  
  METHODS
  In 10 consecutive men viable BCG was directly applied to the condylomata acuminata lesions once weekly for 6 weeks. In nonresponding patients another course of 9 applications was administered for 3 weeks.
  
  
  RESULTS
  A complete response was achieved in 6 of the 10 men after 1 or 2 treatment cycles. All responding patients are disease-free at a median followup of 9.2 months (range 4 to 12). One patient achieved partial regression of the lesions and in 3 the condylomata did not disappear. Side effects were rare and mild. Long-term followup in 6 adjuvant treated patients with rapidly recurrent condylomata acuminata showed no further recurrence after topical BCG in 5 at a median of 30.8 months (range 29 to 50).
  
  
  CONCLUSIONS
  Topical application of viable BCG has therapeutic activity as adjuvant and primary treatment for penile condylomata acuminata with negligible side effects. Long-term followup implies the prevention of recurrent disease.
authors.affiliation: Department of Urology, Medical University of Lübeck, Lübeck, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Böhle
authors.forename: H
authors.initials: H
authors.lastname: Büttner
authors.forename: D
authors.initials: D
authors.lastname: Jocham
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000627:therapeutic use*; D003218:Condylomata Acuminata / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010409:Penile Diseases / Q000188:drug therapy*
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine